+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
MALE
ID06582446

Personalized Whole-Pelvis Hypofractionated Radiotherapy with Prostate Dose Escalation and Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer A Phase II Single-Arm Study

Led by German Oncology Center, Cyprus · Updated on 2026-09-17

30

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating a new approach to personalize radiation therapy for men with high-risk localized prostate cancer using multimodal artificial intelligence MMAI. This phase II study evaluates a combination of treatments including prostate dose escalation with high-dose-rate HDR brachytherapy, two years of androgen deprivation therapy ADT, and ultra-hypofractionated whole-pelvis radiotherapy UHF-RT. The goal is to assess treatment safety and cancer control outcomes in this specific patient group. All participants will receive a standardized treatment regimen involving a single fraction of HDR brachytherapy delivering 15 Gy to the prostate, followed by ultra-hypofractionated external beam radiotherapy to the elective pelvic lymph nodes at 25 Gy over five fractions. Alongside radiation, patients will undergo two years of ADT using luteinizing hormone-releasing hormone agonists or antagonists. The radiation techniques include intensity-modulated and image-guided radiotherapy. This study lasts about three weeks for radiation delivery, with ADT continuing for 24 months. Participants will be monitored closely for side effects and cancer progression over a minimum of five years. Regular assessments will include toxicity evaluations, survival measures, quality of life questionnaires, and blood tests including testosterone levels. Researchers will also analyze MMAI-based risk predictions and seek biomarkers to improve treatment personalization. Follow-up visits are scheduled frequently during and after treatment to track outcomes and safety.

CONDITIONS

Brief Title

Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)

Research Team

E

Elena Pallari, PhD

K

Kristis Vevis, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here